🔎 Trials Near Me

Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Illinois › Champaign

Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Champaign, IL keessatti

Qorannoo 11 Kansara Qara'a Non-Small Cell f Champaign fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Namoota walitti qabaa jiraSadarkaa 3
  • Carle Cancer Center, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04267848

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Namoota walitti qabaa jiraSadarkaa 3
  • Carle Cancer Center, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT07388524

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Namoota walitti qabaa jiraSadarkaa 3
  • Local Institution - 0423, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07361510

Pan-tumor MRD Study

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Carle Health, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Namoota walitti qabaa jiraSadarkaa 2
  • Carle Cancer Center, Urbana · Miili 2 fagaatti
  • The Carle Foundation Hospital, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT03191149

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Namoota walitti qabaa jiraSadarkaa 1/2
  • Carle Cancer Institute, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT04486833

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Namoota walitti qabaa jiraSadarkaa 2
  • Carle Cancer Center, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Wax-2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Namoota walitti qabaa jiraSadarkaa 2
  • Carle Cancer Center, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Cam-2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Namoota walitti qabaa jiraSadarkaa 2
  • Carle Cancer Center, Urbana · Miili 2 fagaatti
18 Minutes · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Namoota walitti qabaa jiraSadarkaa 2/3
  • Carle Cancer Center, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Carle Cancer Center, Urbana · Miili 2 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Bit-2026 · NCT06418204

Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti

Qorannoo biroo Champaign keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.